• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

New migraine-specific pharmacologic agents associated with less efficacy compared to triptans

byYuchen DaiandMichael Pratte
October 11, 2021
in Emergency, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. For pain freedom and relief at 2 hours after dosage, new agents such as lasmiditan, rimegepant, and ubrogepant were associated with a higher odds ratio compared to placebo, but a lower odds ratio compared to most triptans.

2. The lack of cardiovascular risks among new classes of migraine-specific pharmacologic agents may provide alternative treatment options for patients with migraine attacks and cardiovascular contraindications to triptans.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The current standard of care for the treatment of acute migraine centers around triptans, a class of selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonists. More recently, new therapeutic classes of migraine-specific pharmacologic agents have been developed, including 5-hydroxytryptamine1F (5-HT1F) receptor agonists (lasmiditan) and calcitonin gene-related peptide (CGRP) antagonists (rimegepant and ubrogepant). This systematic review and network meta-analysis compared the efficacy of newer agents including 5-HT1F receptor agonists and CGRP antagonists compared to triptans for the treatment of acute migraine attacks. The main endpoint was the odds ratio (OR) for freedom from pain at 2 hours after dosage, where secondary outcomes included ORs for pain relief at 2 hours and any adverse events. Among 64 randomized clinical trials (RCTs) with a total of 46,442 patients, triptans, ditans, and gepants were associated with reduced pain at 2 hours compared to placebo. However, most triptans were associated with reduced pain when compared with newer agents (ditans and gepants), where ditans had the highest risk of adverse events among all treatments and certain triptans carried a higher risk of adverse events compared to gepants. For pain freedom and pain relief at 2 hours after dosage, lasmiditan, rimegepant, and ubrogepant were associated with a higher OR compared to placebo, but a lower OR compared to most triptans. However, the lack of cardiovascular risks among these new classes of migraine-specific pharmacologic agents may provide alternative treatment options for patients with migraine attacks and cardiovascular contraindications to triptans. A limitation of this study was the sole focus on short-term responses and adverse events after a single dose of pharmacologic treatment, where long-term safety and efficacy of gepants and ditans need to be investigated in future clinical studies.

Click to read the study in JAMA Network Open

Relevant Reading: Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial

In-Depth [systematic review and meta-analysis]: This systematic review and network meta-analysis included a total of 64 double-blind RCTs examining current migraine-specific acute treatments (46,442 participants; 74%-87% women; age range, 36-43 years) searched from inception to March 2020 among databases including the Cochrane Register of Controlled Trials, Embase, and PubMed. Data extraction was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline and all network meta-analyses were conducted using a random effects model. Overall, most new pharmacologic agents were associated with reduced pain at 2 hours compared to placebo. However, for pain freedom at 2 hours, triptans were associated with higher ORs compared to new agents including lasmiditan (range: OR, 1.72 [95%CI, 1.06-2.80] to OR, 3.40 [95%CI, 2.12-5.44]), rimegepant (range: OR, 1.58 [95%CI, 1.07-2.33] to OR, 3.13 [95%CI, 2.16-4.52]), and ubrogepant (range: OR, 1.54 [95%CI, 1.00-2.37] to OR, 3.05 [95%CI, 2.02-4.60]). Similarly, for pain relief at 2 hours, triptans were associated with higher ORs vs lasmiditan (range: OR, 1.46 [95%CI, 1.09-1.96] to OR, 3.31 [95%CI, 2.41-4.55]), rimegepant (range: OR, 1.33 [95%CI, 1.01-1.76] to OR, 3.01 [95%CI, 2.33-3.88]), and ubrogepant (range: OR, 1.38 [95%CI, 1.02-1.88] to OR, 3.13 [95%CI, 2.35-4.15]). Among new treatments, comparisons between lasmiditan, rimegepant, and ubrogepant did not yield statistically significant results for both pain freedom and pain relief at 2 hours, where lasmiditan was also found to have the highest risk of any adverse events.

RELATED REPORTS

Children with migraines have elevated risk of anxiety and depressive symptoms and disorders

Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans

Atogepant effective in reducing migraine and headache days

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: headachemigrainemigrainestriptan
Previous Post

Psychological counselling offered by postsecondary institutions may decrease student distress and increase grade point average  

Next Post

U.S. Supreme Court Meets by Phone Due to Coronavirus Pandemic

RelatedReports

Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Children with migraines have elevated risk of anxiety and depressive symptoms and disorders

November 14, 2022
Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans

July 4, 2022
Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Chronic Disease

Atogepant effective in reducing migraine and headache days

October 4, 2021
Galcanezumab reduces the frequency of episodic cluster headaches
Neurology

More omega-3 and less omega-6 fatty acid consumption associated with reduced migraine frequency and severity

September 3, 2021
Next Post

U.S. Supreme Court Meets by Phone Due to Coronavirus Pandemic

Quick Take: Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Tria

Role of endoscopic ultrasonography for differential diagnosis of upper gastrointestinal submucosal lesions

Parents often unaware of adolescents’ suicidal thoughts

Nature exposure during exercise and nature therapy may improve mental health

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options